4021:TSENissan Chemical Corporation Analysis

Technical outlook is bearish: the stock trades at SAR 5.46, below its 20‑day (SAR 5.57), 50‑day (SAR 5.65) and 200‑day (SAR 6.92) moving averages, RSI sits at 45, and the MACD histogram is negative, signalling downward momentum. Liquidity is improving with an increasing volume trend, yet the price is trapped between a support of SAR 5.18 and resistance near SAR 6.03. Valuation is stretched: the DCF fair value is only SAR 2.12, far below the market price, while the trailing P/E of 39 exceeds the industry average of 27, and the P/B of 4.38 is high for a healthcare‑facility operator. Fundamentals are weak: revenue has collapsed (‑99.9% growth), free cash flow is zero, and the payout ratio of 71% on modest earnings raises concerns about dividend sustainability. Market sentiment is overly optimistic, reflected by an extreme‑greed Fear & Greed index (91.5).